Novartis, Ionis drug failure spurs questions
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a result with important implications for cardiovascular drug research. Dive Brief: An RNA drug from Novartis and Ionis Pharmaceuticals failed to reduce the risk of heart attacks, strokes and death in a clinical trial, an outcome [...]









